-
1
-
-
0034697846
-
Identification of a novel FGF, FGF-21, preferentially expressed in the liver
-
Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000; 1492(1): 203-206.
-
(2000)
Biochim Biophys Acta
, vol.1492
, Issue.1
, pp. 203-206
-
-
Nishimura, T.1
Nakatake, Y.2
Konishi, M.3
Itoh, N.4
-
2
-
-
18144364350
-
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
-
Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16(2): 159-178.
-
(2005)
Cytokine Growth Factor Rev
, vol.16
, Issue.2
, pp. 159-178
-
-
Presta, M.1
Dell'Era, P.2
Mitola, S.3
Moroni, E.4
Ronca, R.5
Rusnati, M.6
-
3
-
-
4744372082
-
Evolution of the Fgf and Fgfr gene families
-
Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20(11): 563-569.
-
(2004)
Trends Genet
, vol.20
, Issue.11
, pp. 563-569
-
-
Itoh, N.1
Ornitz, D.M.2
-
4
-
-
0033763097
-
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
-
White KE, Evans WE, O'Riordan JLH, Speer MC, Econs MJ, Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26(3): 345-348.
-
(2000)
Nat Genet
, vol.26
, Issue.3
, pp. 345-348
-
-
White, K.E.1
Evans, W.E.2
O'Riordan, J.L.H.3
Speer, M.C.4
Econs, M.J.5
Lorenz-Depiereux, B.6
Grabowski, M.7
Meitinger, T.8
Strom, T.M.9
-
5
-
-
14344279878
-
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
-
Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98(11): 6500-6505.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, Issue.11
, pp. 6500-6505
-
-
Shimada, T.1
Mizutani, S.2
Muto, T.3
Yoneya, T.4
Hino, R.5
Takeda, S.6
Takeuchi, Y.7
Fujita, T.8
Fukumoto, S.9
Yamashita, T.10
-
6
-
-
0034703619
-
Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain
-
Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000; 277(2): 494-498.
-
(2000)
Biochem Biophys Res Commun
, vol.277
, Issue.2
, pp. 494-498
-
-
Yamashita, T.1
Yoshioka, M.2
Itoh, N.3
-
7
-
-
0033579972
-
Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain
-
Nishimura T, Utsunomiya Y, Hoshikawa M, Ohuchi H, Itoh N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 1999; 1444(1): 148-151.
-
(1999)
Biochim Biophys Acta
, vol.1444
, Issue.1
, pp. 148-151
-
-
Nishimura, T.1
Utsunomiya, Y.2
Hoshikawa, M.3
Ohuchi, H.4
Itoh, N.5
-
8
-
-
27844546989
-
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
-
Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2(4): 217-225.
-
(2005)
Cell Metab
, vol.2
, Issue.4
, pp. 217-225
-
-
Inagaki, T.1
Choi, M.2
Moschetta, A.3
Peng, L.4
Cummins, C.L.5
McDonald, J.G.6
Luo, G.7
Jones, S.A.8
Goodwin, B.9
Richardson, J.A.10
Gerard, R.D.11
Repa, J.J.12
Mangelsdorf, D.J.13
Kliewer, S.A.14
-
9
-
-
33751115468
-
Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man
-
Lundåsen T, Gälman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260(6): 530-536.
-
(2006)
J Intern Med
, vol.260
, Issue.6
, pp. 530-536
-
-
Lundåsen, T.1
Gälman, C.2
Angelin, B.3
Rudling, M.4
-
10
-
-
34047260591
-
FGF23 is a hormone-regulating phosphate metabolism-unique biological characteristics of FGF23
-
Fukumoto S, Yamashita T. FGF23 is a hormone-regulating phosphate metabolism-unique biological characteristics of FGF23. Bone 2007; 40(5): 1190-1195.
-
(2007)
Bone
, vol.40
, Issue.5
, pp. 1190-1195
-
-
Fukumoto, S.1
Yamashita, T.2
-
11
-
-
20444435873
-
FGF-21 as a novel metabolic regulator
-
Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115(6): 1627-1635.
-
(2005)
J Clin Invest
, vol.115
, Issue.6
, pp. 1627-1635
-
-
Kharitonenkov, A.1
Shiyanova, T.L.2
Koester, A.3
Ford, A.M.4
Micanovic, R.5
Galbreath, E.J.6
Sandusky, G.E.7
Hammond, L.J.8
Moyers, J.S.9
Owens, R.A.10
Gromada, J.11
Brozinick, J.T.12
Hawkins, E.D.13
Wroblewski, V.J.14
Li, D.S.15
Mehrbod, F.16
Jaskunas, S.R.17
Shanafelt, A.B.18
-
12
-
-
38549092079
-
Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases
-
Kharitonenkov A, Shanafelt AB. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs 2008; 22(1): 37-44.
-
(2008)
BioDrugs
, vol.22
, Issue.1
, pp. 37-44
-
-
Kharitonenkov, A.1
Shanafelt, A.B.2
-
13
-
-
33646578195
-
Regulation of fibroblast growth factor-23 signaling by klotho
-
Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281(10): 6120-6123.
-
(2006)
J Biol Chem
, vol.281
, Issue.10
, pp. 6120-6123
-
-
Kurosu, H.1
Ogawa, Y.2
Miyoshi, M.3
Yamamoto, M.4
Nandi, A.5
Rosenblatt, K.P.6
Baum, M.G.7
Schiavi, S.8
Hu, M.C.9
Moe, O.W.10
Kuro-O, M.11
-
14
-
-
33845631059
-
Klotho converts canonical FGF receptor into a specific receptor for FGF23
-
Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444(7120): 770-774.
-
(2006)
Nature
, vol.444
, Issue.7120
, pp. 770-774
-
-
Urakawa, I.1
Yamazaki, Y.2
Shimada, T.3
Iijima, K.4
Hasegawa, H.5
Okawa, K.6
Fujita, T.7
Fukumoto, S.8
Yamashita, T.9
-
15
-
-
34848869695
-
Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21
-
Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282(37): 26687-26695.
-
(2007)
J Biol Chem
, vol.282
, Issue.37
, pp. 26687-26695
-
-
Kurosu, H.1
Choi, M.2
Ogawa, Y.3
Dickson, A.S.4
Goetz, R.5
Eliseenkova, A.V.6
Mohammadi, M.7
Rosenblatt, K.P.8
Kliewer, S.A.9
Kuro-O, M.10
-
16
-
-
34249697012
-
BetaKlotho is required for metabolic activity of fibroblast growth factor 21
-
Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, Eliseenkova AV, Mohammadi M, Kuro-o M. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 2007; 104(18): 7432-7437.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, Issue.18
, pp. 7432-7437
-
-
Ogawa, Y.1
Kurosu, H.2
Yamamoto, M.3
Nandi, A.4
Rosenblatt, K.P.5
Goetz, R.6
Eliseenkova, A.V.7
Mohammadi, M.8
Kuro-O, M.9
-
17
-
-
39149091423
-
FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho
-
Kharitonenkov A, Dunbar JD, Bina HA, Bright S, Moyers JS, Zhang C, Ding L, Micanovic R, Mehrbod SF, Knierman MD, Hale JE, Coskun T, Shanafelt AB. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 2008; 215(1): 1-7.
-
(2008)
J Cell Physiol
, vol.215
, Issue.1
, pp. 1-7
-
-
Kharitonenkov, A.1
Dunbar, J.D.2
Bina, H.A.3
Bright, S.4
Moyers, J.S.5
Zhang, C.6
Ding, L.7
Micanovic, R.8
Mehrbod, S.F.9
Knierman, M.D.10
Hale, J.E.11
Coskun, T.12
Shanafelt, A.B.13
-
18
-
-
84865741904
-
βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism
-
Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ, Kliewer SA. βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 2012; 16(3): 387-393.
-
(2012)
Cell Metab
, vol.16
, Issue.3
, pp. 387-393
-
-
Ding, X.1
Boney-Montoya, J.2
Owen, B.M.3
Bookout, A.L.4
Coate, K.C.5
Mangelsdorf, D.J.6
Kliewer, S.A.7
-
19
-
-
57349098220
-
Fibroblast growth factor 21 corrects obesity in mice
-
Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149(12): 6018-6027.
-
(2008)
Endocrinology
, vol.149
, Issue.12
, pp. 6018-6027
-
-
Coskun, T.1
Bina, H.A.2
Schneider, M.A.3
Dunbar, J.D.4
Hu, C.C.5
Chen, Y.6
Moller, D.E.7
Kharitonenkov, A.8
-
20
-
-
61649127208
-
Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice
-
Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Véniant MM. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58(1): 250-259.
-
(2009)
Diabetes
, vol.58
, Issue.1
, pp. 250-259
-
-
Xu, J.1
Lloyd, D.J.2
Hale, C.3
Stanislaus, S.4
Chen, M.5
Sivits, G.6
Vonderfecht, S.7
Hecht, R.8
Li, Y.S.9
Lindberg, R.A.10
Chen, J.L.11
Jung, D.Y.12
Zhang, Z.13
Ko, H.J.14
Kim, J.K.15
Véniant, M.M.16
-
21
-
-
33846418834
-
The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
-
Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148(2): 774-781.
-
(2007)
Endocrinology
, vol.148
, Issue.2
, pp. 774-781
-
-
Kharitonenkov, A.1
Wroblewski, V.J.2
Koester, A.3
Chen, Y.F.4
Clutinger, C.K.5
Tigno, X.T.6
Hansen, B.C.7
Shanafelt, A.B.8
Etgen, G.J.9
-
22
-
-
33750587755
-
Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways
-
Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, Gromada J. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006; 55(9): 2470-2478.
-
(2006)
Diabetes
, vol.55
, Issue.9
, pp. 2470-2478
-
-
Wente, W.1
Efanov, A.M.2
Brenner, M.3
Kharitonenkov, A.4
Köster, A.5
Sandusky, G.E.6
Sewing, S.7
Treinies, I.8
Zitzer, H.9
Gromada, J.10
-
23
-
-
69249093921
-
Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity
-
Berglund ED, Li CY, Bina HA, Lynes SE, Michael MD, Shanafelt AB, Kharitonenkov A, Wasserman DH. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009; 150(9): 4084-4093.
-
(2009)
Endocrinology
, vol.150
, Issue.9
, pp. 4084-4093
-
-
Berglund, E.D.1
Li, C.Y.2
Bina, H.A.3
Lynes, S.E.4
Michael, M.D.5
Shanafelt, A.B.6
Kharitonenkov, A.7
Wasserman, D.H.8
-
24
-
-
84863116228
-
Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ
-
Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, Goetz R, Mohammadi M, Gerard RD, Dechow PC, Mangelsdorf DJ, Kliewer SA, Wan Y. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc Natl Acad Sci USA 2012; 109(8): 3143-3148.
-
(2012)
Proc Natl Acad Sci USA
, vol.109
, Issue.8
, pp. 3143-3148
-
-
Wei, W.1
Dutchak, P.A.2
Wang, X.3
Ding, X.4
Wang, X.5
Bookout, A.L.6
Goetz, R.7
Mohammadi, M.8
Gerard, R.D.9
Dechow, P.C.10
Mangelsdorf, D.J.11
Kliewer, S.A.12
Wan, Y.13
-
25
-
-
34249711964
-
Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states
-
Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5(6): 426-437.
-
(2007)
Cell Metab
, vol.5
, Issue.6
, pp. 426-437
-
-
Badman, M.K.1
Pissios, P.2
Kennedy, A.R.3
Koukos, G.4
Flier, J.S.5
Maratos-Flier, E.6
-
26
-
-
34249686631
-
Endocrine regulation of the fasting response by PPARalphamediated induction of fibroblast growth factor 21
-
Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA. Endocrine regulation of the fasting response by PPARalphamediated induction of fibroblast growth factor 21. Cell Metab 2007; 5(6): 415-425.
-
(2007)
Cell Metab
, vol.5
, Issue.6
, pp. 415-425
-
-
Inagaki, T.1
Dutchak, P.2
Zhao, G.3
Ding, X.4
Gautron, L.5
Parameswara, V.6
Li, Y.7
Goetz, R.8
Mohammadi, M.9
Esser, V.10
Elmquist, J.K.11
Gerard, R.D.12
Burgess, S.C.13
Hammer, R.E.14
Mangelsdorf, D.J.15
Kliewer, S.A.16
-
27
-
-
34447265235
-
PPARalpha is a key regulator of hepatic FGF21
-
Lundåsen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, Alexson SE, Rudling M. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 2007; 360(2): 437-440.
-
(2007)
Biochem Biophys Res Commun
, vol.360
, Issue.2
, pp. 437-440
-
-
Lundåsen, T.1
Hunt, M.C.2
Nilsson, L.M.3
Sanyal, S.4
Angelin, B.5
Alexson, S.E.6
Rudling, M.7
-
28
-
-
77249099832
-
Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat
-
Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab 2010; 11(3): 206-212.
-
(2010)
Cell Metab
, vol.11
, Issue.3
, pp. 206-212
-
-
Hondares, E.1
Rosell, M.2
Gonzalez, F.J.3
Giralt, M.4
Iglesias, R.5
Villarroya, F.6
-
29
-
-
34249677947
-
FGF21: a missing link in the biology of fasting
-
Reitman ML. FGF21: a missing link in the biology of fasting. Cell Metab 2007; 5(6): 405-407.
-
(2007)
Cell Metab
, vol.5
, Issue.6
, pp. 405-407
-
-
Reitman, M.L.1
-
30
-
-
84863012459
-
Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones
-
Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 2012; 148(3): 556-567.
-
(2012)
Cell
, vol.148
, Issue.3
, pp. 556-567
-
-
Dutchak, P.A.1
Katafuchi, T.2
Bookout, A.L.3
Choi, J.H.4
Yu, R.T.5
Mangelsdorf, D.J.6
Kliewer, S.A.7
-
31
-
-
0028127946
-
Nutritional regulation of the insulin-like growth factors
-
Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15(1): 80-101.
-
(1994)
Endocr Rev
, vol.15
, Issue.1
, pp. 80-101
-
-
Thissen, J.P.1
Ketelslegers, J.M.2
Underwood, L.E.3
-
32
-
-
45649085226
-
Inhibition of growth hormone signaling by the fastinginduced hormone FGF21
-
Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fastinginduced hormone FGF21. Cell Metab 2008; 8(1): 77-83.
-
(2008)
Cell Metab
, vol.8
, Issue.1
, pp. 77-83
-
-
Inagaki, T.1
Lin, V.Y.2
Goetz, R.3
Mohammadi, M.4
Mangelsdorf, D.J.5
Kliewer, S.A.6
-
33
-
-
80053409251
-
Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes
-
Chen W, Hoo RL, Konishi M, Itoh N, Lee PC, Ye HY, Lam KS, Xu A. Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J Biol Chem 2011; 286(40): 34559-34566.
-
(2011)
J Biol Chem
, vol.286
, Issue.40
, pp. 34559-34566
-
-
Chen, W.1
Hoo, R.L.2
Konishi, M.3
Itoh, N.4
Lee, P.C.5
Ye, H.Y.6
Lam, K.S.7
Xu, A.8
-
34
-
-
79960743932
-
Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21
-
Chartoumpekis DV, Habeos IG, Ziros PG, Psyrogiannis AI, Kyriazopoulou VE, Papavassiliou AG. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol Med 2011; 17(7-8): 736-740.
-
(2011)
Mol Med
, vol.17
, Issue.7-8
, pp. 736-740
-
-
Chartoumpekis, D.V.1
Habeos, I.G.2
Ziros, P.G.3
Psyrogiannis, A.I.4
Kyriazopoulou, V.E.5
Papavassiliou, A.G.6
-
35
-
-
79953886306
-
Thermogenic activation induces FGF21 expression and release in brown adipose tissue
-
Hondares E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, Mampel T, Villarroya F. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem 2011; 286(15): 12983-12990.
-
(2011)
J Biol Chem
, vol.286
, Issue.15
, pp. 12983-12990
-
-
Hondares, E.1
Iglesias, R.2
Giralt, A.3
Gonzalez, F.J.4
Giralt, M.5
Mampel, T.6
Villarroya, F.7
-
36
-
-
0037251008
-
Cold-induced recruitment of brown adipose tissue thermogenesis
-
Klingenspor M. Cold-induced recruitment of brown adipose tissue thermogenesis. Exp Physiol 2003; 88(1): 141-148.
-
(2003)
Exp Physiol
, vol.88
, Issue.1
, pp. 141-148
-
-
Klingenspor, M.1
-
37
-
-
0029872696
-
Thermoregulation with age: restoration of beta(3)-adrenergic responsiveness in brown adipose tissue by cold exposure
-
Scarpace PJ, Tse C, Matheny M. Thermoregulation with age: restoration of beta(3)-adrenergic responsiveness in brown adipose tissue by cold exposure. Proc Soc Exp Biol Med 1996; 211(4): 374-380.
-
(1996)
Proc Soc Exp Biol Med
, vol.211
, Issue.4
, pp. 374-380
-
-
Scarpace, P.J.1
Tse, C.2
Matheny, M.3
-
38
-
-
0027030305
-
Importance of sympathetic nerves for the stimulatory effect of cold exposure on glucose utilization in brown adipose tissue
-
Takahashi A, Shimazu T, Maruyama Y. Importance of sympathetic nerves for the stimulatory effect of cold exposure on glucose utilization in brown adipose tissue. Jpn J Physiol 1992; 42(4): 653-664.
-
(1992)
Jpn J Physiol
, vol.42
, Issue.4
, pp. 653-664
-
-
Takahashi, A.1
Shimazu, T.2
Maruyama, Y.3
-
39
-
-
84863012022
-
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis
-
Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, Wu J, Kharitonenkov A, Flier JS, Maratos-Flier E, Spiegelman BM. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev 2012; 26(3): 271-281.
-
(2012)
Genes Dev
, vol.26
, Issue.3
, pp. 271-281
-
-
Fisher, F.M.1
Kleiner, S.2
Douris, N.3
Fox, E.C.4
Mepani, R.J.5
Verdeguer, F.6
Wu, J.7
Kharitonenkov, A.8
Flier, J.S.9
Maratos-Flier, E.10
Spiegelman, B.M.11
-
40
-
-
48349127924
-
The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man
-
Gälman C, Lundåsen T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, Dahlin M, Amark P, Angelin B, Rudling M. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008; 8(2): 169-174.
-
(2008)
Cell Metab
, vol.8
, Issue.2
, pp. 169-174
-
-
Gälman, C.1
Lundåsen, T.2
Kharitonenkov, A.3
Bina, H.A.4
Eriksson, M.5
Hafström, I.6
Dahlin, M.7
Amark, P.8
Angelin, B.9
Rudling, M.10
-
41
-
-
69949107891
-
Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man
-
Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab 2009; 94(9): 3594-3601.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, Issue.9
, pp. 3594-3601
-
-
Christodoulides, C.1
Dyson, P.2
Sprecher, D.3
Tsintzas, K.4
Karpe, F.5
-
42
-
-
77955474305
-
Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease
-
Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML, Maratos-Flier E. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139(2): 456-463.
-
(2010)
Gastroenterology
, vol.139
, Issue.2
, pp. 456-463
-
-
Dushay, J.1
Chui, P.C.2
Gopalakrishnan, G.S.3
Varela-Rey, M.4
Crawley, M.5
Fisher, F.M.6
Badman, M.K.7
Martinez-Chantar, M.L.8
Maratos-Flier, E.9
-
43
-
-
51649118899
-
Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa
-
Dostálová I, Kaválková P, Haluzíková D, Lacinová Z, Mráz M, Papezová H, Haluzík M. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008; 93(9): 3627-3632.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, Issue.9
, pp. 3627-3632
-
-
Dostálová, I.1
Kaválková, P.2
Haluzíková, D.3
Lacinová, Z.4
Mráz, M.5
Papezová, H.6
Haluzík, M.7
-
44
-
-
75149195216
-
Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa
-
Fazeli PK, Misra M, Goldstein M, Miller KK, Klibanski A. Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. J Clin Endocrinol Metab 2010; 95(1): 369-374.
-
(2010)
J Clin Endocrinol Metab
, vol.95
, Issue.1
, pp. 369-374
-
-
Fazeli, P.K.1
Misra, M.2
Goldstein, M.3
Miller, K.K.4
Klibanski, A.5
-
45
-
-
39449127028
-
Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus
-
Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, Tang Y, Liu H, Boden G. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116(1): 65-68.
-
(2008)
Exp Clin Endocrinol Diabetes
, vol.116
, Issue.1
, pp. 65-68
-
-
Chen, W.W.1
Li, L.2
Yang, G.Y.3
Li, K.4
Qi, X.Y.5
Zhu, W.6
Tang, Y.7
Liu, H.8
Boden, G.9
-
46
-
-
68149091653
-
Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance
-
Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009; 32(8): 1542-1546.
-
(2009)
Diabetes Care
, vol.32
, Issue.8
, pp. 1542-1546
-
-
Chavez, A.O.1
Molina-Carrion, M.2
Abdul-Ghani, M.A.3
Folli, F.4
Defronzo, R.A.5
Tripathy, D.6
-
47
-
-
63849189712
-
Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity
-
Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, Matoulek M, Dostalova I, Humenanska V, Haluzik M. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009; 71(3): 369-375.
-
(2009)
Clin Endocrinol (Oxf)
, vol.71
, Issue.3
, pp. 369-375
-
-
Mraz, M.1
Bartlova, M.2
Lacinova, Z.3
Michalsky, D.4
Kasalicky, M.5
Haluzikova, D.6
Matoulek, M.7
Dostalova, I.8
Humenanska, V.9
Haluzik, M.10
-
48
-
-
77956276954
-
Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels
-
Cuevas-Ramos D, Almeda-Valdes P, Gómez-Pérez FJ, Meza-Arana CE, Cruz-Bautista I, Arellano-Campos O, Navarrete-López M, Aguilar-Salinas CA. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. Eur J Endocrinol 2010; 163(3): 469-477.
-
(2010)
Eur J Endocrinol
, vol.163
, Issue.3
, pp. 469-477
-
-
Cuevas-Ramos, D.1
Almeda-Valdes, P.2
Gómez-Pérez, F.J.3
Meza-Arana, C.E.4
Cruz-Bautista, I.5
Arellano-Campos, O.6
Navarrete-López, M.7
Aguilar-Salinas, C.A.8
-
49
-
-
66749106885
-
Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects
-
Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, Jia W. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009; 94(6): 2151-2156.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, Issue.6
, pp. 2151-2156
-
-
Li, H.1
Bao, Y.2
Xu, A.3
Pan, X.4
Lu, J.5
Wu, H.6
Lu, H.7
Xiang, K.8
Jia, W.9
-
50
-
-
77957359658
-
Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride
-
Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, Jia W. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010; 53(5): 934-940.
-
(2010)
J Hepatol
, vol.53
, Issue.5
, pp. 934-940
-
-
Li, H.1
Fang, Q.2
Gao, F.3
Fan, J.4
Zhou, J.5
Wang, X.6
Zhang, H.7
Pan, X.8
Bao, Y.9
Xiang, K.10
Xu, A.11
Jia, W.12
-
51
-
-
77950546742
-
Evaluation of concentrations of FGF-21 - a new adipocytokine in type 2 diabetes
-
Matuszek B, Lenart-Lipińska M, Duma D, Solski J, Nowakowski A. Evaluation of concentrations of FGF-21 - a new adipocytokine in type 2 diabetes. Endokrynol Pol 2010; 61(1): 50-54.
-
(2010)
Endokrynol Pol
, vol.61
, Issue.1
, pp. 50-54
-
-
Matuszek, B.1
Lenart-Lipińska, M.2
Duma, D.3
Solski, J.4
Nowakowski, A.5
-
52
-
-
77956519052
-
Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease
-
Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010; 40(10): 887-892.
-
(2010)
Eur J Clin Invest
, vol.40
, Issue.10
, pp. 887-892
-
-
Yilmaz, Y.1
Eren, F.2
Yonal, O.3
Kurt, R.4
Aktas, B.5
Celikel, C.A.6
Ozdogan, O.7
Imeryuz, N.8
Kalayci, C.9
Avsar, E.10
-
53
-
-
48349146527
-
Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
-
Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, Xu A. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57(5): 1246-1253.
-
(2008)
Diabetes
, vol.57
, Issue.5
, pp. 1246-1253
-
-
Zhang, X.1
Yeung, D.C.2
Karpisek, M.3
Stejskal, D.4
Zhou, Z.G.5
Liu, F.6
Wong, R.L.7
Chow, W.S.8
Tso, A.W.9
Lam, K.S.10
Xu, A.11
-
54
-
-
78049297991
-
Obesity is a fibroblast growth factor 21 (FGF21)-resistant state
-
Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59(11): 2781-2789.
-
(2010)
Diabetes
, vol.59
, Issue.11
, pp. 2781-2789
-
-
Fisher, F.M.1
Chui, P.C.2
Antonellis, P.J.3
Bina, H.A.4
Kharitonenkov, A.5
Flier, J.S.6
Maratos-Flier, E.7
-
55
-
-
84455199475
-
Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance
-
Hale C, Chen MM, Stanislaus S, Chinookoswong N, Hager T, Wang M, Véniant MM, Xu J. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 2012; 153(1): 69-80.
-
(2012)
Endocrinology
, vol.153
, Issue.1
, pp. 69-80
-
-
Hale, C.1
Chen, M.M.2
Stanislaus, S.3
Chinookoswong, N.4
Hager, T.5
Wang, M.6
Véniant, M.M.7
Xu, J.8
|